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Mutations in the metabolic enzymes isocitrate
dehydrogenase-1 (IDH1) and IDH2 that produce the
oncometabolite D-2-hydroxyglutarate (2-HG) occur
frequently in human acute myeloid leukemia (AML).
2-HG modulates numerous biological pathways
implicated in malignant transformation, but the
contribution of mutant IDH proteins to maintenance
and progression of AML in vivo is currently unknown.
To answer this crucial question we have generated
transgenic mice that express IDH2R140Q in an on/
off- and tissue-specific manner using a tetracy-
cline-inducible system. We found that IDH2R140Q
can cooperate with overexpression of HoxA9 and
Meis1a and with mutations in FMS-like tyrosine
kinase 3 (FLT3) to drive acute leukemia in vivo.
Critically, we show that genetic deinduction of
mutant IDH2 in leukemic cells in vivo has profound
effects on their growth and/or maintenance. Our
data demonstrate the proto-oncogenic role of
mutant IDH2 and support its relevance as a thera-
peutic target for the treatment of human AML.
INTRODUCTION
The isocitrate dehydrogenase (IDH) family of enzymes catalyzes
the oxidative decarboxylation of isocitrate to a-ketoglutarate
(a-KG) and carbon dioxide. Mutations in active site arginines of
IDH1 and IDH2 have recently been identified in 20% of acute
myeloid leukemias (AMLs) (Cancer Genome Atlas Research
Network, 2013; Mardis et al., 2009), as well as in a range of
other malignancies including glioblastoma, chondrosarcoma,
and prostate cancer (Amary et al., 2011; Kang et al., 2009;CParsons et al., 2008). Mutations confer on the enzymes a novel
ability to produce D-2-hydroxyglutarate (2-HG), a molecule that
is structurally similar to a-KG and can act as a competitive
inhibitor of a-KG-dependent dioxygenases that in turn regulate
a wide array of biological processes including DNA and histone
demethylation, collagen maturation, and the hypoxic response
(Dang et al., 2009; Ward et al., 2010; Xu et al., 2011). In AML,
patient IDH mutations are associated with a normal karyotype
and often co-occur with other genetic lesions including internal
tandem duplication in FMS-like tyrosine kinase 3 (Flt3ITD) and
mutations that promote the cytoplasmic localization of Nucleo-
phosmin 1 (NPMc+) (Patel et al., 2012).
Mutant IDH proteins have been proposed as attractive drug
targets and molecules that block the production of 2-HG have
recently been reported (Popovici-Muller et al., 2012; Wang
et al., 2013). Expression of mutant IDH1 or IDH2 proteins is suf-
ficient to block differentiation of hematopoietic cells in vitro as
well as in vivo and can be reversed by inhibitor treatment (Fig-
ueroa et al., 2010; Losman et al., 2013; Sasaki et al., 2012;
Wang et al., 2013). Retroviral transduction of IDH mutations in
combination with additional oncogenes into primary mouse
bone marrow cells followed by transplantation have been shown
to drive leukemia development (Chaturvedi et al., 2013; Chen
et al., 2013); however, the central question of whether mutant
IDH1 and IDH2 proteins are required for leukemia maintenance
in vivo remains yet to be answered. Herein we address this ques-
tion through the generation and characterization of transgenic
murine models where expression of IDH2R140Q is conditional
and regulatable.RESULTS
Generation and Characterization of IDH2R140Q
Transgenic Mice
To develop a mouse model of IDH2R140Q mutation that has the
capacity to be both tissue-specific and on/off-inducible, weell Stem Cell 14, 329–341, March 6, 2014 ª2014 Elsevier Inc. 329
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Figure 1. IDH2R140Q-tMiceDemonstrate Extramedullary Hematopoiesis Characterized by Spleen Enlargement and Expansion of Hematopoi-
etic Stem/Progenitor Cells
(A) Schematic depicting the strategy for generation of an inducible IDH2R140Q allele in the mouse. Following Flp-mediated recombination, the IDH2R140Q cDNA
flanked by a tetracycline response element (TRE) and a protamine-1 poly-A cassette is integrated into the ColA1 locus. The PGK promoter drives hygromycin
resistance, allowing selection of integrants.
(B) 2-HG in BM MNCs measured by LC-MS following 8 weeks of transgene induction.
(C) Representative flow cytometry analysis of bone marrow mononuclear cells and splenocytes from mice treated with doxycycline for 8 weeks or 7 months.
Numbers indicate cells within the gate as a percentage of all living cells in the sample.
(legend continued on next page)
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activator (tTA) system. Briefly, the IDH2R140Q cDNA was cloned
downstream of a TRE followed by a protamine-1 polyA cassette
(Fisher et al., 2001) and targeted into the mouse Collagen A1
locus of C2-embryonic stem cells (ESCs) using Flp-recombi-
nase-mediated genomic integration (Beard et al., 2006) (Figures
1A and S1A available online). Chimeric mice harboring the
inducible IDH2R140Q allele were backcrossed into the C57BL/6
background and then crossed to mice that constitutively
express the M2 reverse tTA from the ROSA26 locus (ROSA26-
M2) (Hochedlinger et al., 2005). Compound IDH2R140Q+/;
ROSA26-M2+/ (hereafter referred to as IDH2R140Q-t) were born
at Mendelian ratios (data not shown) and appeared normal and
were compared to single transgenic (i.e., IDH2R140Q+/ or
ROSA26-M2+/) or wild-type littermates (hereafter referred to
as controls).
Due to the documented frequency of IDH mutations in AML
patients (Cancer GenomeAtlas Research Network, 2013;Mardis
et al., 2009; Patel et al., 2012), we chose to focus specifically on
the hematopoietic system of our transgenic mice. IDH2R140Q
expression was induced in animals at 3 weeks of age by
introducing doxycycline in the chow. Quantitative reverse-tran-
scriptase PCR (qRT-PCR) using primers specific for the trans-
gene confirmed IDH2R140Q mRNA expression in both mature
and immature bone marrow cells from IDH2R140Q-t animals
(Figure S1C).Western blot analysis using an antibody that recog-
nizes both the mutant IDH2R140Q and the endogenous wild-type
IDH2 proteins revealed that the total levels of IDH2 in the bone
marrow of IDH2R140Q-t animals were increased by approximately
2-fold in comparison with controls (Figure S1B). Because the
level of endogenous Idh2 mRNA was unaffected by transgene
expression (data not shown), these data suggest that the ratio
of wild-type tomutant protein in our system is approximately 1:1.
The IDH2R140Q mutation, as well as other cancer-associated
mutations in IDH1 and IDH2, has been shown to lead to the pro-
duction of the oncometabolite 2-hydroxyglutarate (2-HG) (Dang
et al., 2009; Ward et al., 2010). 2-HG accumulates in IDHmutant
cancer cells at lowmM concentrations and can also be detected
in the serumof patients withmutant IDHAML (Gross et al., 2010).
We used liquid chromatography-mass spectrometry (LC-MS) to
quantify 2-HG in both serum (Figure S1E) and isolated bone
marrow mononuclear cells (BM MNCs) (Figure 1B) from our
mice. As expected, high levels of 2-HG were detected only in
IDH2R140Q-t animals.
To confirm that transgene expression and 2-HG production
could be reversed in vivo, mice that had been on a doxycycline
diet for a period of 8 weeks were placed on a diet without
doxycycline for 2 weeks. Following this period of deinduction,
both transgene expression and serum 2-HG levels dropped
significantly and returned almost to basal levels (Figures S1D
and S1E). Together these data demonstrate that we have gener-
ated an inducible model of the cancer-associated IDH2R140Q
mutation in which transgene expression and the consequent(D) Spleen weights of mice following 8 weeks of doxycycline treatment.
(E) Percentage of cKit+Sca1+Lin (KSL) cells in the spleens of mice following 8 w
(F) Percentage of KSL cells in the bone marrow of mice following 7 months of do
(G) Percentage of CD48CD150+KSL hematopoietic stem cells in the bone marr
Error bars, mean ± SEM; p value calculated using a two-tailed unpaired Student
Cproduction of 2-HG can be regulated by administration of
doxycycline.
Expression of IDH2R140Q in the Bone Marrow Results in
Aberrant Hematopoiesis in Vivo
In order to establish the impact of IDH2R140Q expression on
normal hematopoietic stem/progenitor cells (HSPCs) as well as
lineage development in vivo, we undertook a detailed analysis
of hematopoiesis in our transgenic animals. Eight weeks after
transgene induction, IDH2R140Q-t and control peripheral blood
cell counts showed no differences (Figures S1F–S1H). Likewise,
there were no alterations in the numbers of hematopoietic stem
cells, myeloid progenitors, or mature B, T, or myeloid cells in the
bone marrow (Figures S1I–S1O). However, the spleens of
IDH2R140Q-t mice were approximately 1.3-fold larger (99.05 ±
4.851mg versus 77.69 ± 4.54mg for the controls; p < 0.005, Stu-
dent’s t test) (Figure 1D) and fluorescence-activated cell sorting
(FACS) analysis revealed significant extramedullary hematopoie-
sis, as evidenced by increased numbers of cKit+Sca1+Lin (KSL)
HSPCs (Figures 1C and 1E).
To assess the longer-term effect of IDH2R140Q mutation, we
analyzed mice following 7 months of continuous transgene in-
duction. In addition to the changes observed at earlier time
points, IDH2R140Q-t mice also had increased numbers of KSL
cells in the bone marrow compared to controls (Figures 1C and
1F). Five out of ten mutants also displayed an expansion of the
long-term hematopoietic stem cell (LT-HSC) compartment
(CD48CD150+ KSL), although overall this trend was not statis-
tically significant (Figures 1C and 1G). To extend our findings we
performed competitive bone marrow transplantation assays
in which sorted KSL cells from IDH2R140Q-t and control mice
(CD45.2+) were transplanted into sublethally irradiated recipients
(CD45.1+). In this assay, IDH2R140Q-t HSPCs showed no differ-
ence in repopulation capacity compared to control HSPCs for
at least 16 weeks after transplantation (Figures S1P–S1S).
IDH2R140Q Expression in HSPCs Drives a Block of
Erythroid Differentiation in Vitro
Deregulated hematopoietic differentiation is frequently observed
in AML and 2-HG has been shown to induce a partial block of dif-
ferentiation in the erythroid leukemia cell line TF-1 (Losman et al.,
2013; Wang et al., 2013). We therefore sought to investigate the
effect of IDH2R140Q on differentiation of primary hematopoietic
cells using a well-established methylcellulose differentiation
assay. Following 8 weeks of transgene induction, we sorted
KSL cells from IDH2R140Q-t and control mice and performed
colony-forming unit (CFU) assays using semisolid medium with
cytokines formulated to drive differentiation into the myeloid
and erythroid lineages (MethoCult GF M3434). In the initial
experiments, doxycycline was added to the medium to ensure
continued transgene expression throughout the differentiation
process. Strikingly, we observed a potent block of differentiation
in IDH2R140Q-t HSPCs compared with controls (Figure 2A).eeks of doxycycline treatment.
xycycline treatment.
ow of mice following 7 months of doxycycline treatment.
’s t test. See also Figure S1.
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Figure 2. IDH2R140Q-t Induces aBlock of Erythroid Differentiation inKSLCells That Is Reversible byGenetic Deinduction of the Transgene and
by a Specific Inhibitor of Mutant IDH2
(A) Methylcellulose CFU-GEMM assay using KSL cells sorted from IDH2R140Q-t or control mice following 8 weeks of doxycycline treatment. Doxycycline was
added to the media to maintain transgene expression throughout the differentiation process (n = 7 biological replicates/group).
(B) Methylcellulose CFU-GEMM assay done as in (A) but with or without adding doxycycline to the medium (n = 3 biological replicates/group).
(C and D) Methylcellulose CFU-GEMM assay done as in (A), with doxycycline in the medium and with or without the mutant IDH2 inhibitor AGI-6780. 2-HG was
quantified by LC-MS in cells collected from the assay after 7 days of culture. b.q.l., below quantitative limit (C). Colonies were scored (n = 4 biological replicates/
group) in (D).
Error bars, mean ± SEM; p value calculated using a two-tailed unpaired Student’s t test. See also Figure S2.
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was unaffected, the number of erythroid colonies was severely
reduced (19.5 ± 1.3 in the controls versus 3.6 ± 0.9 in
IDH2R140Q-t; p < 0.0001, Student’s t test). Notably, when cells
from the first plating were collected and replated, IDH2R140Q-t
cells formed more colonies in the second plating when
compared with controls. IDH2R140Q-t cells could also be serially
replated at least five times, whereas control cells no longer
formed colonies after the third plating (Figure S2A).
To determine if the block of differentiation induced by IDH2
mutation in our model can be reversed, we performed a series
of experiments using both genetic and pharmacological
inactivation of IDH2R140Q. First, we compared differentiation of
IDH2R140Q-t and control KSL cells in the presence or absence
of doxycycline. We sorted cells from mice following 8 weeks of
in vivo transgene induction and then cultured them in CFU
assays either with or without doxycycline. We confirmed that
within 72 hr of doxycycline-free culture, transgene expression332 Cell Stem Cell 14, 329–341, March 6, 2014 ª2014 Elsevier Inc.was efficiently silenced (Figure S2B). Excitingly, upon silencing
IDH2R140Q, differentiation of mutant cells was restored to wild-
type levels, demonstrating that continued expression of the
mutant protein is required for the block of differentiation
(Figure 2B).
Next we used a specific inhibitor of IDH2R140Q (AGI-6780) that
has recently been shown to block production of 2-HG by the
mutant protein (Wang et al., 2013). We confirmed that in our sys-
tem 5 mM of the compound was able to reduce 2-HG production
in mutant cells by 75% (1.29 ± 0.29 mM in untreated cells
versus 0.34 ± 0.04 mM in AGI-6780-treated cells; p < 0.05,
Student’s t test) (Figure 2C). Similar to genetic deinduction,
AGI-6780 completely reversed the block of differentiation in
IDH2R140Q-t KSL cells (Figure 2D). AGI-6780 also reversed
aberrant colony formation in the second and third plating (Fig-
ure S2C). Taken together our data demonstrate that mutant
IDH proteins are sufficient to induce defects in the differentiation
of primary hematopoietic cells. Critically, we have shown that
Figure 3. Identification of a Transcriptional Signature Associated with the IDH2R140Q-Induced Block of Differentiation
(A and B) Microarray analysis of cells cultured for 3 days in the methylcellulose CFU-GEMM assay (nR 3 biological replicates/group). Hierarchical clustering of
significantly altered genes (p < 0.05, fold change >1.5) is shown. Green, downregulated in IDH2R140Q-t cells; red, upregulated in IDH2R140Q-t cells (A). Pathway
enrichment analysis shows genes that are downregulated in IDH2R140Q-t cells (green) or upregulated (red) in IDH2R140Q-t cells. The significance of the enrichment
for each pathway (based on the false discovery rate q value) is proportional to the size of the gray box (i.e., the larger the gray box, the more significant the
enrichment) (B).
(C) qRT-PCR analysis of cells cultured as in (A) and (B) but with or without AGI-6780. For each of the transcripts examined, pharmacological inhibition of 2-HG
production at least partially reverses transcriptional changes in IDH2R140Q-t cells. Error bars, mean ± SEM.
See also Figure S3 and Tables S1, S2, and S3.
Cell Stem Cell
Mutant IDH2 Is Required for Leukemia Maintenancethese effects are reversible by pharmacological inhibition of
2-HG production by the mutant protein.
Mutant IDH proteins have been demonstrated to affect
multiple biological pathways in a cell-context-dependent
manner. We sought to explore the transcriptional signature
that was associated with the block of erythroid differentiation
and so we performed global gene expression microarray
analysis. In order to identify genes that are responsible for
the block of differentiation, rather than a consequence of it,
we sorted KSL cells as previously, but cultured them in
MethoCult GF M3434 for only 3 days prior to RNA extraction.
At this stage, cells had undergone multiple rounds of division,
but 70% of cells retained an undifferentiated morphology
(data not shown). Unsupervised hierarchical clustering revealedCa clear separation of control and IDH2R140Q-t samples (Figures
3A and S3A) and gene set enrichment analysis identified multi-
ple pathways that were deregulated in mutant cells (Figure 3B).
In particular, IDH2R140Q-t cells displayed reduced levels of
transcripts activated by the transcription factor GATA1, a mas-
ter regulator of erythroid differentiation (Fujiwara et al., 1996).
Mutant cells also displayed activation of the hypoxia and
TNF-a pathways. To validate our microarray findings and to
determine whether the transcriptional signature induced by
mutant IDH2 is reversible, we performed qRT-PCR analysis
on a subset of genes that were identified as being altered
and included control and IDH2R140Q-t samples that were treated
with AGI-6780 (Figure 3C). For each of the transcripts exam-
ined, AGI-6780 at least partially reversed the changes inducedell Stem Cell 14, 329–341, March 6, 2014 ª2014 Elsevier Inc. 333
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Figure 4. Continued Expression of IDH2R140Q Is Required for Proliferation and/or Maintenance of HoxA9/Meis1a-Transformed Leukemic
Cells
(A) Schematic outlining the strategy for randomized deinduction experiments.
(B) Representative FACS plots of bone marrow from secondary recipients untreated or treated with doxycycline. Continued expression of IDH2R140Q is essential
for proliferation and/or maintenance of GFP/YFP+ leukemic cells and the onset of leukemia.
(C) Percentage of GFP/YFP+ cells in the bone marrow of secondary recipients untreated or treated with doxycycline (n = 5 recipients on doxycycline, n = 3
recipients off doxycycline).
(legend continued on next page)
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that 2-HG-dependent effects are rapidly reversible. We also
sorted megakaryocyte-erythroid progenitors (MEPs) from con-
trol and IDH2R140Q-t animals and found that Bcl6, identified in
our in vitro analysis, was also consistently upregulated in
MEPs in vivo (Figure S3B).
Continued Expression of IDH2R140Q Is Essential
for Maintenance of HoxA9/Meis1a-Transformed
Leukemic Cells
IDH mutations have been implicated in cancer but their ability to
contribute to the maintenance of established disease in vivo has
not been demonstrated. IDH2R140Q-t mice followed for 1 year
of continuous doxycycline treatment did not develop leukemia,
suggesting that additional genetic events are required for cancer
development. This prompted us to investigate a well-established
surrogate model of AML using retroviral overexpression of the
homeobox proteins HoxA9 and Meis1a (Kroon et al., 1998).
KSL cells isolated from IDH2R140Q+/+;ROSA26-M2+/ (hereafter
referred to as IDH2R140Qhm-t) that had been treated with doxycy-
cline were transduced with retroviruses encoding HoxA9
(MSCV-HoxA9-GFP) and Meis1a (MSCV-Meis1a-YFP) and
transplanted into syngeneic sublethally irradiated recipients
(Figure 4A). Following 7 weeks of administering continued
doxycycline treatment, we observed an expansion of GFP/
YFP+ cells in the peripheral blood of primary recipients (not
shown), indicating the establishment of an early leukemic or
preleukemic state. These animals were then euthanized, GFP/
YFP+ bone marrow cells were sorted (Figure S4A), and 105 cells
were retransplanted into secondary syngeneic recipients. After
an initial 3 day period of administering doxycycline treatment
to allow engraftment, we performed randomized deinduction
with some of the recipients being taken off doxycycline food
and thereby experiencing genetic inactivation of IDH2R140Q
(Figure 4A).
After 8 weeks, all (5/5) doxycycline-treated secondary recipi-
ents developed AML, with their bone marrow being composed
almost exclusively of GFP/YFP+Mac1+ and GFP/YFP+Mac1+
cKit+ cells (Figures 4B, 4C, and S4B). All five recipients showed
virtually identical disease development (Figure S4B), strongly
suggesting that additional stochastic events that may influence
the proliferative or immuno-phenotypic properties of the cells
had not occurred after transplantation. We confirmed overex-
pression of HoxA9 andMeis1a in doxycycline-treated recipients
using qRT-PCR (Figure S4D). Strikingly, all (3/3) secondary
recipients that had been withdrawn from doxycycline had no
clearly discernible GFP/YFP+ population and normal ratios
of myeloid and lymphoid cells, demonstrating that the vast
majority of leukemic blasts had been eliminated (Figures 4B,
4C, and S4B).(D) PCR on genomic DNA isolated from BM MNCs of doxycycline-treated and -u
Meis1a-YFP. Vector (i.e., MSCV-HoxA9-GFP or MSCV-Meis1a-YFP, respectively
(E) Percentage of GFP/YFP+ cells in the bone marrow of secondary recipients
plantation. Randomized deinduction was performed 2 weeks after transplantatio
(F) Percentage of blasts in the bone marrow of secondary recipients untreated
Randomized deinduction was performed 2 weeks after transplantation (n = 2–3 re
stained bone marrow cytospins.
See also Figure S4.
CTo determine if a small number of leukemia-initiating cells that
was not detectable by FACS remained and could act as a source
of disease relapse, we used a PCR assay to detect MSCV-
HoxA9-GFP and MSCV-Meis1a-YFP with primers designed to
span introns so as not to amplify endogenous HoxA9 and
Meis1a from genomic DNA. Using this assay and following an
extended cycling protocol, we could not detect a reservoir of
transduced cells in the bone marrow of recipients that had
been withdrawn from doxycycline (Figure 4D). These data
strongly suggest that all, or at least the vast majority, of leukemic
cells, including the leukemia-initiating cell population, were
eliminated upon genetic deactivation of IDH2R140Q.
Next, we aimed to characterize the kinetics of disease regres-
sion upon IDH2R140Q deinduction. As before, sublethally irradi-
ated C57BL/6 recipients were transplanted with 105 GFP/YFP+
cells sorted from a preleukemic IDH2R140Qhm-t/HoxA9/Meis1a
primary donor. This time, however, all secondary recipients
were treated with doxycycline for 14 days, at which point two
recipients were sacrificed and FACS analysis revealed that
their bonemarrow comprised50%GFP/YFP+ cells (Figure 4E).
We then performed randomized deinduction and sacrificed
recipients for analysis every 2 weeks. Consistent with what has
recently been reported in vitro upon pharmacological inhibition
of IDH2R140Q in human and mouse AML cells (Chen et al.,
2013; Wang et al., 2013), animals withdrawn from doxycycline
treatment initially showed a hyperproliferation of GFP/YFP+
leukemic cells (Figure 4E; 4 week time point, 2 weeks off doxycy-
cline food), followed by a reduction and elimination. In total, six
of eight animals across the two independent experiments that
had been withdrawn from doxycycline treatment for at least
4 weeks showed elimination of leukemic cells from the bone
marrow and restoration of normal hematopoiesis (Figure S4C).
FACS, morphological, and transcriptional analyses of bone
marrow at the 4 week time point suggested that upon IDH2R140Q
deinduction, leukemic cells underwent differentiation. Despite
having almost twice asmanyGFP/YFP+ cells in the bonemarrow
at this time point, recipients that had been withdrawn from doxy-
cycline treatment had similar numbers of blasts to doxycycline-
treated recipients (Figure 4F), implying a greatly increased ratio
of morphologically differentiated to undifferentiated cells within
the GFP/YFP+ fraction. Similarly, analysis of the stem/progenitor
marker cKit showed a reduced ratio of cKit+ to cKit cells upon
deinduction (Figure S4E). Finally, we explored a panel of tran-
scripts identified in our microarray analysis, and found that a
subset of genes (Atf3, Ptgs2, and S100A9) that were upregulated
in IDH2R140Q-t KSL cells undergoing differentiation in vitro were
downregulated upon transgene deinduction in vivo in leukemic
cells (Figure S4F). Taken together, our data demonstrate that
HSPCs, which initially acquire an IDH2 mutation and subse-
quently become transformed by additional genetic events, atntreated recipients using primers specific for MSCV-HoxA9-GFP and MSCV-
) DNA (V) and wild-type C57BL/6 genomic DNA (G) were used as controls.
untreated or treated with doxycycline at various time points following trans-
n (n = 2–3 recipients/time point/treatment).
or treated with doxycycline at various time-points following transplantation.
cipients/time point/treatment). Blasts were scored on May-Grunwald-Giemsa-
ell Stem Cell 14, 329–341, March 6, 2014 ª2014 Elsevier Inc. 335
Figure 5. IDH2R140Q and Flt3ITD Cooperate in Leukemia Initiation
(A) Representative H&E staining of tissue sections from IDH2R140Q-t;Flt3ITD compound transgenic animals and an Flt3ITD control animal. Compound transgenic
animals develop acute myeloid (AML-like) and lymphoid (ALL-like) malignancies whereas Flt3ITD animals developmyeloproliferative disease (MPD). Left panels: a
compound transgenic animal diagnosed with AML-like disease. Apoptotic debris and numerous tingible body macrophages (magnified in inset, upper left panel)
characteristic of highly proliferative disease are evident throughout. Infiltration of intermediate-sized blast-like immature mononuclear cells (magnified in inset,
upper right panel) is evident in the red pulp of the spleen, the liver, and kidney. Middle panels: a compound transgenic animal diagnosed with ALL-like disease.
T lymphoblasts (confirmed by immunohistochemical staining using anti-CD3ε antibody, not shown) with high-grade morphology are present in the thymus,
spleen, liver, and lung. Numerous mitoses are present, characteristic of a rapidly proliferative disease. Right panels: MPD in an Flt3ITD animal with a hypercellular
bone marrow with myeloid maturation and increased myeloid cells in the spleen. Original magnification, 6003.
(legend continued on next page)
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the mutant IDH2 protein for maintenance.
Genetic Deinduction of IDH2R140Q Has Profound Effects
on Leukemic Blasts in a Compound IDH2R140Q;Flt3ITD
AML Model
We next sought to explore the function of mutant IDH2 in a sys-
tem that more closely recapitulates the genetics of human AML.
Internal tandem duplication in the receptor tyrosine kinase Flt3
is a frequent event in AML patients, is associated with poor
prognosis, and co-occurs with mutations in IDH1 or IDH2 (Patel
et al., 2012). Knockin Flt3ITD transgenic mice develop lethal
meyloproliferative neoplasms (MPNs), but not overt leukemia
(Chu et al., 2012; Li et al., 2008; Rau et al., 2013). Notably,
combining the Flt3ITD allele with other mutations observed in
AML patients can transform this MPN into full-blown acute
leukemia (Rau et al., 2013).
To test whether the IDH2R140Q mutation can cooperate with
Flt3ITD to drive disease progression, we generated compound
IDH2R140Q-t;Flt3ITD animals and treated them with doxycycline.
Excitingly, and in contrast to Flt3ITD single transgenic littermate
controls, compound animals developed acute leukemias (Fig-
ures 5A and 5B). In our cohort, IDH2R140Q-t;Flt3ITD animals dis-
played a significantly reduced overall survival compared with
Flt3ITD controls (median survival of 229 days versus 352 days,
respectively; p = 0.0299, Mantel-Cox test) (Figure S5A). Consis-
tent with previous published observations (Chu et al., 2012;
Li et al., 2008; Rau et al., 2013), the MPD in Flt3ITD animals
was characterized by a hypercellular bone marrow with myeloid
predominance and maturation (Figure 5A). The leukemias that
developed in compound transgenic mice, on the other hand,
were characterized by infiltration of large monomorphic blasts
into hematopoietic (bone marrow, spleen, thymus) and non-
hematopoietic (liver, lung, kidney) organs. We analyzed bone
marrow cells, splenocytes, and thymocytes by FACS and found
that the immuno-phenotype of cells from different animals, and
occasionally from different organs within the same animal,
varied (Figure 5B). We identified leukemias that displayed both
myeloid (CD3εB220Mac1lowcKit+) and lymphoid (Mac1
B220CD3ε+CD8+CD4 and Mac1B220CD3εCD8+CD4+)
markers (Figure 5B).
Our data strongly suggest that IDH2R140Q is a bona fide
cooperating oncogene in vivo. However, in order to further
confirm the malignant nature of the disease and the diagnosis
of acute leukemia that developed in IDH2R140Q-t;Flt3ITD animals,
we performed transplantation experiments (Kogan et al., 2002).
To this end, we transplanted leukemic cells into sublethally irra-
diated CD45.1+ syngeneic recipients and treated them with
doxycycline. In this system, leukemic cells compete with normal
recipient bone marrow cells in the niche and we were able to
directly track their fate as they express the alternate surface(B) Examples of FACS plots demonstrating the types of acute leukemia diagnosed
CD3ε+cKit+ lymphoblasts in the thymus and bone marrow; cells in the thymus a
exclusively Mac1+/low and a population of Mac1lowcKit+ immature cells is eviden
(C and D) Primary AML (BM MNCs from donor #5517) and ALL (thymocytes from
treatedwith doxycycline. FACS plots demonstrate the overwhelmingmajority of d
loss of lineage markers (Mac1 and CD3ε, respectively) upon serial transplantatio
See also Figure S5.
Cantigen CD45.2. In two independent experiments we used BM
MNCs or thymocytes derived from two different compound
transgenic animals (#5517 and #12063, respectively). In both
instances, the leukemic cells were able to recapitulate a lethal
leukemia in transplanted recipients, and notably upon trans-
plantation they mostly lost the expression of mature lineage
markers (Mac1 for #5517 and CD3ε for #12063) (Figures 5C,
5D, and S5B–S5D). The disease derived from donor #5517
was used in serial transplantation experiments and became
more aggressive and homogenous, and in secondary recipients
the bone marrow was composed almost exclusively of CD45.2+
CD3εB220Mac1 immature blasts.
Having established a model where mutant IDH2 contributes
to leukemia initiation, our next step was to determine whether
genetic inactivation of IDH2R140Q in this context had an effect
on leukemia maintenance and/or progression. Due to the
variable onset of disease and the time required to generate
large cohorts of compound transgenic animals, we focused
our efforts on a transplantation-based ‘‘chimeric’’ model. We
used primary leukemia cells from the bone marrow of donor
#5517 to perform randomized deinduction experiments. As
previously, leukemic cells were allowed to engraft for 3 days in
the presence of doxycycline, and then half of the recipients
were taken off doxycycline food (Figure 6A).We followed animals
until they became moribund and had to be euthanized. We
observed no clear differences in survival of doxycycline-treated
and -untreated animals across primary, secondary, or tertiary
transplantation experiments. Analysis of serum 2-HG levels
confirmed that the metabolite returned to baseline levels
following transgene deinduction (Figure S5E). All animals that
were caught prior to succumbing to disease were subjected to
a detailed histopathological analysis. Infiltration of leukemic cells
into nonhematopoietic organs was similar between the two
treatment cohorts (Figure S5F). In contrast, there was a clear
difference with respect to bone marrow involvement. The bone
marrow of animals treated with doxycycline was composed
predominantly of blasts whereas animals in the untreated group
displayed fewer blasts and marked differentiation (Figures 6B–
6E). The morphological analysis was in agreement with the
percentage chimerism as assessed by CD45.1/CD45.2 staining.
Thus, inhibition of IDH2R140Q in acute leukemia in the context of
a cooperating Flt3ITD mutation, at least in some cases, results in
reduced proliferation and/or differentiation of leukemic blasts.
DISCUSSION
IDH mutations have been proposed as attractive targets for the
development of novel anticancer therapeutics because specific
small molecule inhibitors can directly block the neomorphic
activity of the enzymes, namely the production of 2-HG
(Popovici-Muller et al., 2012; Wang et al., 2013). However, thein IDH2R140Q-t;Flt3ITD compound transgenic animals. Left panels: presence of
re exclusively CD8+CD4. Right panels: cells in the bone marrow are almost
t; in the thymus of the same animal, CD3εCD8+ lymphoblasts are present.
donor #12063) cells recapitulate a lethal leukemia in transplanted recipients
onor-derived (CD45.2+) cells in the bonemarrow ofmoribund recipients and the
n.
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Figure 6. Mutant IDH2 Contributes to Leukemia Initiation and Maintenance in the Context of a Cooperating Flt3ITD Lesion
(A) Schematic outlining the strategy for randomized deinduction experiments using AML cells from recipient #5517.
(B) May-Grunwald-Giemsa-stained bone marrow cytospins showing presence of leukemic blasts and differentiated myeloid cells in doxycycline-treated
and -untreated recipients, respectively.
(C) Examples of FACS plots showing reduced donor chimerism in untreated versus doxycycline-treated recipients based on differential staining for the cell
surface markers CD45.1/CD45.2.
(D and E) Genetic deinduction of IDH2R140Q expression by withdrawal of doxycycline has a profound effect on the proliferation and/or differentiation of leukemic
blasts in vivo. Percentage of donor-derived (CD45.2+) cells (D) and blasts (E) in the bone marrow of primary, secondary, or tertiary recipients untreated or treated
with doxycycline is shown. Blasts were scored onMay-Grunwald-Giemsa-stained bonemarrow cytospins. Randomized deinduction was performed 3 days after
transplantation.
(F) Model for the role of IDH2R140Q in primary HSPCs and in the maintenance of leukemia.
See also Figure S5.
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remains poorly understood, and importantly, whether or not
cancer cells are addicted to 2-HG in their native niche for growth
and/or maintenance is yet to be determined.
We have generated a mouse model of IDH2R140Q, the most
common IDH2 mutation observed in human AML. To our
knowledge this is the first transgenic allele of mutant IDH2338 Cell Stem Cell 14, 329–341, March 6, 2014 ª2014 Elsevier Inc.reported to date. In our model, expression of the transgene
and the consequent production of 2-HG is on/off inducible and
comparable to that observed in AML patients, providing a valu-
able system for evaluating the biological effects of deinduction
as well as the pharmacological efficacy of potential 2-HG
inhibitors. Consistent with what was previously reported for a
knockin model of IDH1R132H (Sasaki et al., 2012), we found that
Cell Stem Cell
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hematopoietic compartment characterized by an expansion of
HSPCs within the spleen and bone marrow, but on its own it
was not sufficient for leukemogenesis, at least within the time
frame of our experiment.
In a well-established multilineage differentiation assay,
IDH2R140Q-t KSL cells formed a greatly reduced number of
erythroid colonies, but an equivalent number of myeloid col-
onies, in comparison with controls. We established a tran-
scriptional signature associated with this block of erythroid
differentiation and identified downregulation of GATA1 activity
and upregulation of the hypoxia and TNF-a pathways as being
potentially important in this process. Inhibition of GATA1 function
was previously reported in mutant IDH AML patients (Figueroa
et al., 2010). The effects of mutant IDH proteins on the hypoxia
pathway have been disputed with some studies reporting hyper-
activation (Xu et al., 2011) and others reporting inactivation
(Koivunen et al., 2012; Losman et al., 2013), albeit in different
systems. In our model, the observed transcriptional changes
strongly argue in favor of activation of hypoxic signaling.
Importantly, both the block of differentiation and the altered
transcriptional profile in IDH2R140Q-t cells is reversible by the
mutant IDH2 inhibitor AGI-6780. Our results confirm and expand
on previous studies showing that mutant IDH proteins can
induce a reversible block of differentiation in the erythroid
leukemia line TF-1 (Losman et al., 2013; Wang et al., 2013). We
conclude that at least under some conditions, production of
2-HG by mutant IDH proteins may not only block differentiation
of hematopoietic cells, it may in fact bias it toward the myeloid
lineage.
Though studies on the effects of IDH mutations on primary
and leukemic cells in vitro or on HSPC function and lineage
development in vivo provide important mechanistic insights,
they fail to answer the most crucial question of whether mutant
IDH2 is required for leukemia initiation and maintenance in vivo
in the presence of a functional niche. To address this, we used
two compound transgenic models in which IDH mutation was
combined with activation of additional oncogenes. HoxA9 and
Meis1a are downstream targets of numerous pathways de-
regulated in AML and forced coexpression of these two proteins
is sufficient to transform murine HSPCs (Kroon et al., 1998;
Wang et al., 2010). Notably, when this powerful combination
was introduced into IDH2 mutant KSL cells, the proliferation
and/or maintenance of the resultant leukemic cells were depen-
dent on continued expression of IDH2R140Q. Within 2 weeks of
genetic deinduction of mutant IDH, we observed evidence of
differentiation, and 2 weeks later, 6/8 animals showed complete
remission with elimination of any detectable leukemic cells.
Interestingly, we found that Atf3, which has been implicated as
a positive regulator of TGF-b signaling and was shown to
enhance cancer-initiating cell activity in breast cancer cells,
was downregulated upon IDH2R140Q inactivation (Yin et al.,
2010). Our results are both surprising and encouraging in that
we have modeled a situation where IDH mutation occurs as an
early event and leukemic transformation occurs as a result of
subsequent genetic ‘‘hits.’’ Indeed, IDH mutation is considered
an early event in the evolution of AML as well as other cancer
types including glioma (Kandoth et al., 2013; Watanabe et al.,
2009). Thus our results strongly suggest that IDH mutation mayCestablish a state of oncogene addiction even in a genetic setting
where mutant IDH is not required for cancer initiation.
By generating compound IDH2R140Q;Flt3ITD transgenic
mutants, we demonstrated that IDH2R140Q cooperates with
Flt3ITD in leukemia initiation in vivo, strongly suggesting that
IDH mutations are cooperative tumorigenic drivers in AML.
Our results are coherent with two recent studies demonstrating
that retroviral transduction of IDH mutations into mouse bone
marrow cells can cooperate with other oncogenic stimuli in
leukemogenesis (Chaturvedi et al., 2013; Chen et al., 2013).
Retroviral models, though highly useful, are limited by
numerous factors including artificial levels of transgene expres-
sion and random integration of the provirus into the genome.
Our transgenic approach demonstrates the additional require-
ments and consequences of mutant IDH expression at phy-
siologically relevant levels, as well as those of mutant IDH
deinduction in vivo. Indeed the latency of disease development
in IDH2R140Q;Flt3ITD mice suggests that additional mutations
were required for full leukemic transformation. Recent se-
quencing efforts by the Cancer Genome Atlas have revealed
that the median number of recurrent mutations in adult normal
karyotype AML is approximately five (Cancer Genome Atlas
Research Network, 2013). The spectrum of disease that devel-
oped in different transgenic animals in our model may be
explained by the nature of additional mutations or by the type
of cell in which they occurred. Indeed, numerous transgenic
models develop different types of hematopoietic malignancies
among animals of the same genotype (Rau et al., 2013; Yilmaz
et al., 2006).
As with our HoxA9/Meis1a transduction model, we observed
that genetic inactivation of mutant IDH2 in the context of a
cooperating Flt3ITD lesion had an effect on disease progression,
and though we were unable to show increased survival upon
mutant IDH2 deinduction, we did demonstrate effects on the
proliferation and/or differentiation of leukemic blasts. Analysis
of leukemic infiltrates suggested that in this highly aggressive
setting, mice that display a response in the bone marrow may
nonetheless succumb to the disease due to damage of nonhe-
matopoietic organs. Additionally, because a reduction in 2-HG
levels may take some time (based on our measurements in
nonleukemic mice 2 weeks after deinduction), leukemic cells
may cause irreparable damage to the bone marrow niche and/or
to other organs before the cells are eliminated. If that is the case,
inhibition of mutant IDH proteins may synergize with chemo-
therapy or other drugs (in this case Flt3 inhibitors) that produce
more immediate effects.
In summary, our findings, and those of other groups (Losman
et al., 2013; Rohle et al., 2013; Wang et al., 2013), prove that at
least some of the effects of IDH mutation are dependent on
continued production of 2-HG. Critically, we extend previous
work by demonstrating that those effects are reversible in vivo
and addicted to the proto-oncogenic activity of the IDH mutant
enzyme even in a genetic milieu where leukemia initiation is
IDH mutant independent. We therefore validate mutant IDH
proteins as very strong candidates for continued development
of targeted anticancer therapeutics. Our model can serve as
an invaluable tool for evaluating the biological effects of genetic
deinduction of IDH mutations in various genetic settings as
well as the pharmacological efficacy of potential mutant IDH2ell Stem Cell 14, 329–341, March 6, 2014 ª2014 Elsevier Inc. 339
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(Figure 6F).
EXPERIMENTAL PROCEDURES
Transgenic Animals
The tetracycline-inducible IDH2R140Q allele was created following the scheme
shown in Figure 1A and backcrossed into the C57BL/6 background (see Sup-
plemental Experimental Procedures for more information). ROSA26-M2
(Hochedlinger et al., 2005), C57BL/6, and CD45.1+ (B6.SJL-Ptprca Pepcb/
BoyJ) animals were purchased from Jackson Laboratories. Flt3ITD transgenic
(Li et al., 2008) animals were kindly provided by Donald Small and Patrick
Brown from Johns Hopkins University School of Medicine (Baltimore).
To activate transgene expression in vivo, a doxycycline-containing chow
(Harlan Laboratories) was administered to animals at the time of weaning
(3 weeks of age). To deactivate transgene expression, mice were taken off
the doxycycline-containing diet and placed on a regular laboratory rodent
diet. We obtained approval for all animal experiments from the Beth Israel
Deaconess Medical Center IACUC Committee on Animal Research (Protocol
#066-2011; Approved 08/15/2011).
CFU-GEMM Assays
CFU-GEMM assays were performed using MethoCult GF M3434 (StemCell
Technologies) in accordance with the manufacturer’s instructions. Briefly,
KSL cells from control and IDH2R140Q-t mice were isolated by FACS using a
BD FACSAria IIu sorter (Becton Dickinson) (see Supplemental Experimental
Procedures) and 900 cells were added to individual 3 ml aliquots of MethoCult
GF M3434. One microgram per milliliter doxycycline and five micromolar
AGI-6780 (Wang et al., 2013) were added as indicated. Cells were then
plated at a density of 300 cells/dish in duplicate for each biological replicate
and cultured for 7 days at 37C and 5% CO2. Colonies were scored in a
2.5 cm 3 2.5 cm area in the center of each dish using a grid. For the replating
experiment, cells were collected in IMDM media supplemented with 2%
fetal bovine serum (FBS), washed once in PBS, counted, and replated in
MethoCult GF M3434 supplemented with 1 mg/ml doxycycline at a density
of 5,000 cells/dish. Colonies were counted after 7–14 days of culture as above.
Generation of the HoxA9/Meis1a Transduction Model
KSL cells were sorted (see Supplemental Experimental Procedures) from
IDH2R140Qhm-t mice that had been treated with doxycycline for 6 weeks.
Cells were cultured for 8 hr in StemSpan serum free expansion medium
(StemCell Technologies) supplemented with murine SCF, TPO, IL-3, IL-6,
and Flt3-L (PeproTech) on Retronectin-coated (Takara Bio) petri dishes.
Cells were transduced overnight using MSCV-HoxA9-GFP and MSCV-
Meis1a-YFP (kindly provided by Dr. Christian Bach). The next day, cells
were harvested and washed twice with phosphate buffered saline (PBS).
Viable cells were counted following trypan blue staining and 5,000 cells
were injected retro-orbitally into sublethally irradiated (6.5Gr) C57BL/6 recip-
ients. For the initial experiment, secondary transplantation and randomized
deinduction was performed as outlined in Figure 4A. For the repeat experi-
ment, all recipients were maintained on doxycycline food for 2 weeks, at
which time 2 recipients were analyzed to confirm presence of GFP/YFP+
cells in the bone marrow. Randomized deinduction was then performed
with recipients randomly assigned to doxycycline-treated or untreated
groups. Mice were then analyzed every 2 weeks to monitor the kinetics of
disease regression.
Serial Transplantation of IDH2R140Q-t/Flt3ITD Leukemic Cells
Bone marrow cells extracted from the femurs and tibias of a compound trans-
genic animal diagnosed with AML were subjected to red blood cell (RBC) lysis
using ACK lysis buffer (GIBCO), washed twice with PBS supplemented with
2% FBS, passed through a 70 mM strainer, and frozen in FBS supplemented
with 10% dimethyl sulfoxide (DMSO). On the day of transplantation, cells
were thawed at 37C and washed twice in PBS. Viable cells were counted
following trypan blue staining. A hundred thousand donor cells were injected
retro-orbitally into sublethally irradiated (6.5Gr) CD45.1+ recipients. Alterna-
tively, 105 donor cells were mixed with 5 3 105 wild-type CD45.1+ competitor340 Cell Stem Cell 14, 329–341, March 6, 2014 ª2014 Elsevier Inc.cells and injected retro-orbitally into lethally irradiated (9.5Gr) CD45.1+ recipi-
ents. For serial transplantations, the process was repeated using 105 cells from
primary or secondary doxycycline-treated recipients.
Microarray Analysis
KSL cells from control and IDH2R140Q-t mice were cultured for 3 days in
MethoCult GF M3434 (StemCell Technologies) supplemented with 1 mg/ml
doxycycline. All cells were then collected and total RNA was extracted using
Trizol (Ambion) with GlycoBlue (Life Technologies) as a carrier. Two-hundred
nanograms of RNA was hybridized to Affymetrix Mouse Gene 2.1 ST arrays
by the Beth Israel Deaconess Medical Center Genomics and Proteomics
Core. The obtained raw intensity .cel files were normalized by robust multichip
analysis (Bioconductor release 2.12) and differential expression was deter-
mined using the limma Bioconductor package by fitting a linear model. Gene
set enrichment analysis was conducted with the gene sets from the Molecular
Signatures Database (MolSigDB v3.1) (see Supplemental Experimental
Procedures and Table S4 for more information).SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes Supplemental Experimental
Procedures, five figures, and four tables and can be found with this article
online at http://dx.doi.org/10.1016/j.stem.2013.12.016.
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